Germany-based life sciences company Bayer acquired US-based agrochemical producer Monsanto last week for a total consideration of $63bn and is now debating what to do with the latter’s corporate venture capital unit, according to Agfunder.

The success of Monsanto Growth Ventures (MGV) has been lauded by Liam Condon, chief executive of Bayer CropScience, a seed and food security subsidiary of Bayer, but he refused to commit his company to maintaining the unit.

Bayer has traditionally favoured larger investments through its…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?